Oramed Pharmaceuticals Sells its Stake in Entera Bio for $1.15 Million; Buyer Also to Invest $250,000 in Oramed

February 28, 2011

JERUSALEM, February 28, 2011 /PRNewswire-FirstCall/ — Oramed
Pharmaceuticals Inc. (OTCBB: ORMP), a developer of oral drug delivery
systems, announced today that its subsidiary Oramed Ltd. entered into a Share
Purchase Agreement with D.N.A Biomedical Solutions Ltd. (formerly Laser
Detect Systems Ltd.), an Israeli company listed on the Tel Aviv Stock
Exchange, for the sale of most of its holdings in Entera Bio Ltd., for $1.15
, and a commitment by D.N.A to invest $250,000 in Oramed. Oramed will
also transfer to Entera the patent that is currently being licensed to Entera
and will be entitled to receive 3% royalties. See more details below.

Nadav Kidron, Chief Executive Officer of Oramed, commented: “We have made
a strategic decision to focus our resources on our core technology. This
transaction will strengthen our balance sheet and help finance the phase 2
clinical trials of our orally ingestible insulin capsule (ORMD0801). At the
same time, if Entera Bio is successful in its development of products based
on this patent, we stand to gain, as well.”

Currently, Oramed and D.N.A each hold 50% of Entera’s outstanding share
capital on an undiluted basis. Following the transaction Oramed will hold 3%
of Entera’s outstanding share capital on an undiluted basis.

As consideration for the Entera shares, Oramed will receive a promissory
note issued by D.N.A in the principal amount of US $450,000, with an annual
interest rate of 0.45%, to be paid within four months from closing, and
8,404,667 ordinary shares of D.N.A, having an aggregate market value of
approximately US $700,000.

In addition, D.N.A will invest $250,000 in Oramed’s investment round, for
which it will receive 781,250 shares of Oramed common stock and five-year
warrants to purchase 273,438 shares of common stock at an exercise price of
$0.50 per share.

As part of the transaction, Oramed Ltd. and Entera entered into a Patent
Transfer Agreement according to which, Oramed will assign to Entera all of
its right, title and interest in and to the patent that it has licensed to
Entera since August 2010. Under this agreement, Oramed Ltd. is entitled to
receive from Entera royalties of 3% of Entera’s net revenues (as defined in
the agreement) and a license back of that patent for use in respect of
diabetes and influenza. The assigned technology differs from Oramed’s main
delivery technology that is used for oral insulin and is subject to a
different patent application.

The closing of all of the abovementioned transactions will take place
concurrently on the first business day following the satisfaction of all the
closing conditions. If the closing does not occur by March 31, 2011, Oramed
will have the right to terminate the agreements.

Upon the closing, Oramed, Entera and D.N.A will terminate the Joint
Venture Agreement, entered into on June 1, 2010 in connection with the
formation of Entera.

Mr. Zeev Bronfeld, one of D.N.A’s directors and controlling shareholders,
holds more than 5% of Oramed’s outstanding share capital. Accordingly,
pursuant to Israeli law, the closing of the transactions is subject to the
approval of D.N.A’s shareholders.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc. is a technology pioneer in the field of oral
delivery solutions for drugs and vaccines presently delivered via injection.
Oramed is seeking to revolutionize the treatment of diabetes through its
patented flagship product, an orally ingestible insulin capsule currently in
phase 2 clinical trials. Established in 2006, Oramed’s technology is based on
over 25 years of research by top research scientists at Jerusalem’s Hadassah
Medical Center. Oramed’s corporate and R&D headquarters are based in

For more information about Oramed’s clinical development programs, please
visit http://www.oramed.com.

Forward-Looking Statements

Some of the statements contained in this press release are
forward-looking statements which involve known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements of the company, or industry results, to be
materially different from any future results, performance or achievements
expressed or implied by such forward looking statements, including the risk
that the transaction will not be approved by the shareholders of D.N.A, the
risks and uncertainties related to the progress, timing, cost, and results of
clinical trials and product development programs; difficulties or delays in
obtaining regulatory approval for our product candidates; competition from
other pharmaceutical or biotechnology companies; and Oramed’s ability to
obtain additional funding required to conduct its research, development and
commercialization activities. Please refer to Oramed’s filings with the
Securities and Exchange Commission for a comprehensive list of risk factors
that could cause actual results, performance or achievements of Oramed to
differ materially from those expressed or implied in such forward looking
statements. Oramed undertakes no obligation to update or revise any
forward-looking statements.

    Company and Investor Relation Contacts:

    Oramed Pharmaceuticals Inc.
    Tara Horn
    Office: +1-646-240-4193
    Cell: +972-54-334-4318
    Email: tara@oramed.com

SOURCE Oramed Pharmaceuticals Inc.

Source: newswire

comments powered by Disqus